A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant loss of -99.83% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -95.51%. Over the past 30 days, the price of CNSP has fallen by 3.43%. And in the last five days, it has fallen by -0.46%.
Cns Pharmaceuticals Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $89.61 on 12/18/23, while the lowest value for the same period was recorded at $0.10 on 08/16/24.
52-week price history of CNSP Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cns Pharmaceuticals Inc’s current trading price is -99.88% away from its 52-week high, while its distance from the 52-week low is 13.82%. The stock’s price range during this period has varied between$0.10 and $89.61. The Cns Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 11.12 million for the day, a figure considerably lower than their average daily volume of 15.19 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cns Pharmaceuticals Inc (CNSP) has experienced a quarterly decline of -32.06% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 6.25M and boasts a workforce of 5 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.1509, with a change in price of -0.9606. Similarly, Cns Pharmaceuticals Inc recorded 12,473,396 in trading volume during the last 100 days, posting a change of -89.78%.
CNSP’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CNSP stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.
CNSP Stock Stochastic Average
Cns Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 5.00%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 27.79%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 19.07% and 18.48%, respectively.
